Celludoxa Sanovazo-Botanicure Co., Ltd.

Celludoxa Sanovazo

Home Products Celludoxa Sanovazo

Global Radiotherapy Trends

Global cancer cases are projected to increase from 20 million in 2022 to more than 35 million annually by 2050. Approximately 50% of cancer patients will require radiotherapy during treatment.

Radiotherapy-related pain and skin toxicity can significantly impact patient quality of life and treatment adherence, highlighting the need for effective supportive care solutions.

Global Cancer Population

20 Million+

Cancer Cases Worldwide

10 Million+

Patients Receive Radiotherapy Annually

90 %

Of Radiotherapy Patients Develop Radiation-Induced Skin Injury

Product Introduction

Regulatory Approval

Precautions

Celludoxa Sanovazo
Sanovazo received TFDA Class II Medical Device approval in 2020 supported by clinical evidence demonstrating significant reduction of radiotherapy-related pain and discomfort. (License No.: MD 006946)

Product Description
Intended Use

1. Maintains a moist environment for superficial (epidermal) wounds.
2. Intended for the prevention and management of symptoms or minor skin injuries caused by radiation therapy.

ALL_news_research_study_25L14_Irh5kcjEFn

1. Discontinue use and consult a healthcare professional if irritation or allergic reactions occur.
2. External use only. Do not ingest.
3. Children should use under adult supervision.
4. Do not use after the expiration date or more than 3 months after opening.
5. Pregnant or breastfeeding women should use as directed by a physician.

Back to list